Techmediabreaks Longeveron Inc.'S (NASDAQ: LGVN) Lomecel-B(TM) Granted RMAT Designation For The Treatment Of Mild Alzheimer's Disease

(MENAFN- Investor Brand Network) Longeveron (NASDAQ: LGVN) , a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (“FDA”) granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to Lomecel-B(TM) for the treatment of mild Alzheimer's disease. To the company's knowledge based on publicly available information, Lomecel-B, a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer's.“The RMAT designation is an important milestone for Longeveron and the Lomecel-B program that recognizes the potential of our cellular therapy to have a positive impact on patients afflicted with this devastating disease,” said Joshua Hare, co-founder, chief science officer and chairman of the board at Longeveron.“Alzheimer's disease is a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options. In the CLEAR MIND Phase 2a clinical trial, Lomecel-B demonstrated an overall slowing/prevention of disease worsening compared to placebo. The trial achieved the primary safety and secondary efficacy endpoints and showed statistically significant improvements in pre-specified clinical and biomarker endpoints in specific Lomecel-B groups compared to placebo.”

To view the full press release, visit

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The company's lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer's disease, and Aging-related Frailty. The Lomecel-B HLHS program has received three separate and distinct FDA designations: Orphan Drug, Fast Track and Rare Pediatric Disease designations. For more information about the company, visit .

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company's newsroom at

About TechMediaWire

(“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 60+ brands within
Dynamic Brand Portfolio
that delivers :
(1) access to a vast network of wire solutions via
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text“TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published:

Los Angeles, CA

310.299.1717 Office

TechMediaWire is powered by


Investor Brand Network

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.